Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Update on bb2121 CAR T-cell product for MM from EHA 2018

Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús Berdeja of the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, gives an update on bb2121, a promising therapy for patients with heavily pre-treated relapsed/refractory multiple myeloma (MM).